Board Change • May 20
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 4 independent directors (7 non-independent directors). Independent Director Yushuang Pan was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Duyuru • Apr 29
Tongkun Group Co., Ltd., Annual General Meeting, May 20, 2026 Tongkun Group Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: No. 518, Fenghuanghu Avenue, Tongxiang, Zhejiang China Duyuru • Mar 30
Tongkun Group Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Tongkun Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Duyuru • Dec 26
Tongkun Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 22, 2026 Tongkun Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 22, 2026 Duyuru • Sep 30
Tongkun Group Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Tongkun Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Duyuru • Jun 30
Tongkun Group Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Tongkun Group Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Duyuru • Apr 26
Tongkun Group Co., Ltd., Annual General Meeting, May 20, 2025 Tongkun Group Co., Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time. Location: No. 518, Fenghuanghu Avenue, Tongxiang, Zhejiang China Duyuru • Mar 28
Tongkun Group Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Tongkun Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Duyuru • Dec 27
Tongkun Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Tongkun Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.43 profit in 3Q 2023) Third quarter 2024 results: CN¥0.024 loss per share (down from CN¥0.43 profit in 3Q 2023). Revenue: CN¥27.8b (up 12% from 3Q 2023). Net loss: CN¥58.6m (down 107% from profit in 3Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance. Duyuru • Sep 30
Tongkun Group Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Tongkun Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥12.37, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.48 per share. Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.21 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.21 (down from CN¥0.21 in 2Q 2023). Revenue: CN¥27.1b (up 29% from 2Q 2023). Net income: CN¥485.3m (down 19% from 2Q 2023). Profit margin: 1.8% (down from 2.8% in 2Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance. Buy Or Sell Opportunity • Jul 31
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 2.0% to CN¥14.05. The fair value is estimated to be CN¥11.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 15% in 2 years. Earnings are forecast to grow by 148% in the next 2 years. Buy Or Sell Opportunity • Jul 11
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 9.6% to CN¥15.06. The fair value is estimated to be CN¥12.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 151% in the next 2 years. Duyuru • Jun 28
Tongkun Group Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024 Tongkun Group Co., Ltd. announced that they will report first half, 2024 results on Aug 29, 2024 Duyuru • Apr 29
Tongkun Group Co., Ltd., Annual General Meeting, May 21, 2024 Tongkun Group Co., Ltd., Annual General Meeting, May 21, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Tongxiang, Zhejiang China Reported Earnings • Apr 27
Full year 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.055 in FY 2022) Full year 2023 results: EPS: CN¥0.34 (up from CN¥0.055 in FY 2022). Revenue: CN¥82.6b (up 33% from FY 2022). Net income: CN¥797.0m (up CN¥666.8m from FY 2022). Profit margin: 1.0% (up from 0.2% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 54 percentage points per year, which is a significant difference in performance. Duyuru • Mar 30
Tongkun Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Tongkun Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Duyuru • Dec 30
Tongkun Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024 Tongkun Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 27, 2024 New Risk • Oct 29
New major risk - Revenue and earnings growth Earnings have declined by 8.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). Earnings have declined by 8.9% per year over the past 5 years. Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.43 (vs CN¥0.15 loss in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.43 (up from CN¥0.15 loss in 3Q 2022). Revenue: CN¥24.8b (up 43% from 3Q 2022). Net income: CN¥798.3m (up CN¥1.16b from 3Q 2022). Profit margin: 3.2% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Duyuru • Sep 30
Tongkun Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Tongkun Group Co., Ltd. announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 New Risk • Sep 26
New major risk - Revenue and earnings growth Earnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Earnings have declined by 1.7% per year over the past 5 years. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.34 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.21 (down from CN¥0.34 in 2Q 2022). Revenue: CN¥21.0b (up 25% from 2Q 2022). Net income: CN¥595.5m (down 25% from 2Q 2022). Profit margin: 2.8% (down from 4.7% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Duyuru • Jun 28
Tongkun Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Tongkun Group Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Apr 26
Full year 2022 earnings released: EPS: CN¥0.055 (vs CN¥3.23 in FY 2021) Full year 2022 results: EPS: CN¥0.055 (down from CN¥3.23 in FY 2021). Revenue: CN¥62.0b (up 4.8% from FY 2021). Net income: CN¥130.2m (down 98% from FY 2021). Profit margin: 0.2% (down from 13% in FY 2021). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year and the company’s share price has also increased by 4% per year. Duyuru • Feb 17
Tongkun Group Co., Ltd. (SHSE:601233) entered into an agreement to acquire Tongkun (Hong Kong) Investment Co., Ltd. from Tongkun Holding Group Co., Ltd for CNY 2.4 million. Tongkun Group Co., Ltd. (SHSE:601233) entered into an agreement to acquire Tongkun (Hong Kong) Investment Co., Ltd. from Tongkun Holding Group Co., Ltd for CNY 2.4 million on February 15, 2023. Tongkun Group board approves the acquisition. As of December 31, 2022, EBIT of CNY 0 million, total assets of CNY 5.15511619 million, total common equity of CNY 2.34542982 million and net income of CNY -1.93688714 million. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 2 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 29
Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.89 profit in 3Q 2021) Third quarter 2022 results: CN¥0.15 loss per share (down from CN¥0.89 profit in 3Q 2021). Revenue: CN¥17.3b (down 14% from 3Q 2021). Net loss: CN¥366.2m (down 118% from profit in 3Q 2021). Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 29
Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥1.06 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.34 (down from CN¥1.06 in 2Q 2021). Revenue: CN¥16.9b (down 12% from 2Q 2021). Net income: CN¥798.4m (down 67% from 2Q 2021). Profit margin: 4.7% (down from 13% in 2Q 2021). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 23%, compared to a 40% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.76 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.62 (down from CN¥0.76 in 1Q 2021). Revenue: CN¥13.0b (up 17% from 1Q 2021). Net income: CN¥1.50b (down 13% from 1Q 2021). Profit margin: 12% (down from 15% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 13
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: EPS: CN¥3.17 (up from CN¥1.52 in FY 2020). Revenue: CN¥60.1b (up 31% from FY 2020). Net income: CN¥7.32b (up 157% from FY 2020). Profit margin: 12% (up from 6.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 11%, compared to a 46% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Mar 08
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥17.80, the stock trades at a forward P/E ratio of 5x. Average forward P/E is 18x in the Chemicals industry in China. Total returns to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.22 per share. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.89 (vs CN¥0.43 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥20.2b (up 76% from 3Q 2020). Net income: CN¥2.03b (up 157% from 3Q 2020). Profit margin: 10% (up from 6.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 19
Second quarter 2021 earnings released: EPS CN¥1.06 (vs CN¥0.32 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥19.1b (up 40% from 2Q 2020). Net income: CN¥2.42b (up 314% from 2Q 2020). Profit margin: 13% (up from 4.3% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 15% per year. Reported Earnings • Apr 17
Full year 2020 earnings released: EPS CN¥1.52 (vs CN¥1.57 in FY 2019) The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: CN¥45.8b (down 9.4% from FY 2019). Net income: CN¥2.85b (down 1.3% from FY 2019). Profit margin: 6.2% (up from 5.7% in FY 2019). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 7% per year. Valuation Update With 7 Day Price Move • Mar 25
Investor sentiment deteriorated over the past week After last week's 19% share price decline to CN¥19.08, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 22x in the Chemicals industry in China. Total returns to shareholders of 24% over the past three years. Valuation Update With 7 Day Price Move • Feb 11
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥28.69, the stock is trading at a trailing P/E ratio of 23.7x, up from the previous P/E ratio of 20.4x. This compares to an average P/E of 35x in the Chemicals industry in China. Total returns to shareholders over the past three years are 69%. Is New 90 Day High Low • Feb 09
New 90-day high: CN¥27.50 The company is up 55% from its price of CN¥17.73 on 11 November 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.64 per share. Is New 90 Day High Low • Jan 07
New 90-day high: CN¥22.49 The company is up 58% from its price of CN¥14.23 on 09 October 2020. The Chinese market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 18% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥5.54 per share. Valuation Update With 7 Day Price Move • Nov 13
Market bids up stock over the past week After last week's 15% share price gain to CN¥18.40, the stock is trading at a trailing P/E ratio of 15.2x, up from the previous P/E ratio of 13.2x. This compares to an average P/E of 39x in the Chemicals industry in China. Total returns to shareholders over the past three years are 49%. Is New 90 Day High Low • Nov 11
New 90-day high: CN¥16.97 The company is up 10.0% from its price of CN¥15.44 on 13 August 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥4.40 per share. Analyst Estimate Surprise Post Earnings • Nov 01
Third-quarter earnings released: Revenue beats expectations Third-quarter revenue exceeded analyst estimates by 13% at CN¥11.5b. Revenue is forecast to grow 11% over the next year, compared to a 33% growth forecast for the Chemicals industry in China. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥2.24b, up 7.7% from the prior year. Total revenue was CN¥46.2b over the last 12 months, down 3.8% from the prior year. Valuation Update With 7 Day Price Move • Oct 15
Market bids up stock over the past week After last week's 18% share price gain to CN¥16.35, the stock is trading at a trailing P/E ratio of 12x, up from the previous P/E ratio of 10.2x. This compares to an average P/E of 40x in the Chemicals industry in China. Total returns to shareholders over the past three years are 48%. Is New 90 Day High Low • Oct 01
New 90-day low: CN¥13.83 The company is down 1.0% from its price of CN¥14.00 on 03 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥56.21 per share.